However, when agonists activate the AR, it suppresses estrogen-driven cancer growth by altering the genomic distribution of the ER and essential coactivators such as p300 and steroid receptor coactivator 3 (SRC-3) [65]. This evidence concerns the gene NCOA3 and cancer.